Health Official: Studies Show Iran’s Coviran Barekat Coronavirus Vaccine 90% Effective
By Staff, Agencies
An Iranian health official says the latest studies carried out on Iran’s Coviran Barekat coronavirus vaccine have proven its effectiveness to stand at 90 percent after volunteers received a 5-microgram dose.
Hamed Hosseini, the official in charge of the University of Tehran's Clinical Trials Center, made the announcement in an interview on Monday after the second and third phases of clinical studies on the Iranian vaccine officially began.
“Today, 2 volunteers were vaccinated and phases 2 and 3 of the clinical studies on Coviran Barekat started. According to the first-phase studies, the effectiveness of the vaccine in people receiving a 5-microgram dose stands at 90 percent,” Hosseini added.
He noted that through the permission of Iranian Food and Drug Organization, the second and third phases of human trials of the Iranian COVID-19 vaccine will be carried out simultaneously.
Iran in late December began the first phase in the human trial of the homegrown COVID-19 vaccine after successfully completing the initial steps, including tests on animals, and obtaining necessary approvals.
The vaccine, produced by Iranian experts at the Headquarters for Executing the Order of Imam Khomeini, was administered to three volunteers at a ceremony in Tehran, the first of them being Tayyebeh Mokhber, the daughter of the organization’s CEO Mohammad Mokhber.
It is dubbed Coviran Barekat after the pharmaceutical group that developed the vaccine against the coronavirus pandemic.
A total of 56 volunteers would receive two shots administered 14 days apart in the first human trial of the Iranian vaccine and the results will be announced 28 days later.
The vaccine is of the inactivated type, which is made of a virus that is weakened or killed by chemicals.